Infection

Lenacapavir is the first of a new class of antiretrovirals, and it is indicated for persons with multidrug resistance, intolerance, or safety considerations.

Your daily dose of clinical news you may have missed.

One study showed the boosters provide significant protection against hospitalization and ED care and the other found vaccine effectiveness of 84% in older adults.

Physiatrist Monica Verduzco-Gutierrez, MD, highlights the state of long COVID management in the US and says primary care is crucial in diagnosing and treating the new condition.

The vaccination campaign in the US also has prevented more than 18 million hospitalizations and saved $1 trillion in medical costs, according to a modeling study.

The FDA amended Pfizer and Moderna EUAs for updated COVID-19 vaccines to include children as young as age 6 months as holidays and winter weather approach.

Your daily dose of clinical news you may have missed.

The inpatient flu census doubled after Thanksgiving travel and gatherings and ICU beds are full. More at-a-glance stats on Flu in the USA, here.

She reports cough and persistent escalating fever x2 weeks, headache but no neck stiffness. Tachycardia and mild skin pallor seen on PE. What do the lab tests tell you?

Pfizer and BioNTech submitted an application to the FDA for emergency use authorization of their omicron BA.4/BA.5-adapted bivalent COVID-19 vaccines in children aged 6 months to 4 years.

Flu rates are up after the Thanksgiving holiday week, COVID-19 hospitalizations are increasing, and RSV may or may not be on the wane as Christmas approaches.

Your daily dose of clinical news you may have missed.

Analysis of an online survey in the UK found women vs men and higher vs lower BMI were associated with greater likelihood of developing long COVID.

Respiratory syncytial virus is an age-old winter foe that could affect many of your patients this year. Take a minute and scan these facts for a refresher.

Your daily dose of clinical news you may have missed.

One in 7 parents have not discussed vaccines with their child's primary clinician during the 2-year pandemic period, according to a CS Mott Children's Hospital poll.

Overall flu activity is at a 10-year high, according to the CDC's most recent influenza surveillance report, while US hospitals are already overwhelmed.

Early oseltamivir use reduced the length of hospitalization and risk for hospital readmission in children hospitalized with influenza, according to new research.

Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.

I have admitted infants to the hospital every winter for 40 years, yet I still don't have good answers for anxious parents watching their child struggling to breathe.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

Your daily dose of clinical news from Patient Care Online.

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

Elizabeth Sapey, PhD, discusses how the updated treatment recommendations from the World Health Organization may impact future use of remdesivir.

Elizabeth Sapey, PhD, discusses findings from the SOLIDARITY study and similar research on the efficacy of remdesivir for treatment of severe disease.

Elizabeth Sapey, PhD, discusses the updated recommendations and the research that prompted the decision.

This influenza antiviral brush-up slide show reminds you of key features of the 4 FDA-recommended medications, at-a-glance.

WHO: Evidence is lacking for clinical effectiveness of Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.